However, in a large study cohort of 1645 patients having stage I-IV CRC, patients with HER2/neu-positive tumors had worse overall survival (OS) than those with negative HER2/Neu tumors [7]. This evidence concerns the gene ERBB2 and colorectal carcinoma.